What Is Telehealth?

When COVID-19 hit in March 2020, Teladoc Health (TDOC) stock skyrocketed 139% that year as millions of patients suddenly needed remote medical care. What started as pandemic necessity has evolved into a $83.5 billion global market that's fundamentally reshaping how we think about healthcare delivery and investment opportunities. The telehealth revolution isn't just changing medicine—it's creating entirely new asset classes.

Telehealth refers to the remote delivery of healthcare services and clinical information using telecommunications technology, including video calls, mobile apps, remote monitoring devices, and digital platforms. Think of it as the healthcare equivalent of how Netflix transformed entertainment consumption—instead of traveling to a physical location, patients access medical care wherever they are. This encompasses everything from virtual doctor visits and remote patient monitoring to AI-powered diagnostic tools and prescription delivery services. For investors, telehealth represents the digitization of a traditionally analog industry, creating scalable business models with potentially higher margins than brick-and-mortar healthcare.

Consider Amwell (AMWL), which went public in September 2020 at $18 per share. The company's platform connects patients with healthcare providers through video consultations, charging providers a subscription fee plus per-visit costs. Here's how their revenue model works:

In Q3 2023, Amwell reported 4.1 million visits on their platform, generating $62.6 million in quarterly revenue. Compare this to traditional healthcare: a typical doctor's office might see 20-30 patients daily, while telehealth platforms can handle hundreds of consultations simultaneously. However, Amwell's stock has struggled, trading around $2-4 per share in 2023-2024, showing that execution matters more than just market opportunity. Winners like Veracyte (VCYT) focus on specific niches—their remote cancer diagnostics have delivered consistent growth while broader telehealth plays have disappointed.

Professional investors view telehealth through three distinct lenses: platform plays, enabling technology, and vertical integration opportunities. Smart money focuses on companies with defensible moats—proprietary technology, regulatory advantages, or exclusive payer relationships. We're seeing sophisticated investors pivot from pure-play telehealth stocks to healthcare technology companies that integrate virtual care into broader offerings, like CVS Health (CVS) with their HealthHub strategy. The contrarian insight here: the biggest telehealth winners might not be companies you'd recognize as telehealth stocks at all, but traditional healthcare players using virtual care to reduce costs and improve margins.

Common mistakes investors make include:

Telehealth represents healthcare's inevitable digital transformation, but winning investments require understanding the difference between genuine disruption and temporary pandemic boosts. Focus on companies with clear paths to profitability and defensible competitive advantages. The question isn't whether telehealth will reshape healthcare—it's which business models will actually generate sustainable returns for shareholders.